

AMENDMENT B
(37 C.F.R. 1.111)

IN THE CLAIMS:

Please amend claims 1, 3-14 and 21 in accordance with 37 C.F.R. 1.121.

Please add new claim 22.

The claims are attached herein on separate sheets.

AMENDMENT TO CLAIMS

[Deleted material is struck-through and added material is underlined]

1. (Currently Amended) A composition for treating symptoms and conditions associated with aging, the composition including an active ingredient **consisting essentially of comprising:**

one of

an aqueous extract of buckwheat seed,

a fractionation product of an aqueous extract of buckwheat seed, and

a combination of said aqueous extract of buckwheat seed and said fractionation product of said aqueous extract of buckwheat seed,

wherein the active ingredient contains polymers having 4 to 9 monomer units, **said polymers** having a molecular weight of from about 1,000 to about 10,000,

wherein the composition **enhances an activity of protein kinase C (PKC), improves short time memory and alleviates decrease in space cognition caused by aging**
~~activates a function of the brain's activity.~~

2. (Original) The composition according to Claim 1, wherein the aqueous extract of buckwheat seed has a molecular weight of about 1500 or more.

3. (Currently Amended) The composition according to Claim 1, wherein the composition ~~activates the function of the brain's activity for alleviating and treating~~
alleviates and treats symptoms and conditions caused by dementia.

4. (Currently Amended) The composition according to Claim 2, wherein the composition ~~activates the function of the brain's activity for alleviating and treating~~
alleviates and treats symptoms and conditions caused by dementia.

5. (Currently Amended) The composition according to Claim 1, wherein the composition ~~activates the function of the brain's activity for alleviating and treating~~
alleviates and treats symptoms and conditions caused by Alzheimer's syndrome.

6. (Currently Amended) The composition according to Claim 2, wherein the composition ~~activates the function of the brain's activity for alleviating and treating~~
alleviates and treats symptoms and conditions caused by Alzheimer's syndrome.

7. (Currently Amended) The composition according to Claim 1, wherein the composition ~~inhibits~~ ~~activates the function of the brain's activity for inhibiting~~ lipid peroxide.

8. (Currently Amended) The composition according to Claim 2, wherein the composition ~~activates the function of the brain's activity for inhibiting~~ inhibits lipid peroxide.

9. (Currently Amended) The composition according to Claim 1, wherein the composition ~~activates the function of the brain's activity for treating~~ treats hyperlipemia.

10. (Currently Amended) The composition according to Claim 2, wherein the composition ~~activates the function of the brain's activity for treating~~ treats hyperlipemia.

11. (Currently Amended) The composition according to Claim 1, wherein the composition ~~activates the function of the brain's activity for lowering~~ lowers triacylglycerol levels.


12. (Currently Amended) The composition according to Claim 2, wherein the composition ~~activates the function of the brain's activity for lowering~~ lowers triacylglycerol levels.

13. (Currently Amended) The composition according to Claim 1, wherein the composition ~~activates the function of the brain's activity for lowering~~ lowers cholesterol levels.

14. (Currently Amended) The composition according to Claim 2, wherein the composition ~~activates the function of the brain's activity for lowering~~ lowers cholesterol levels.



15. (Original) The composition according to Claim 1, wherein the polymer having four to nine monomer units comprises a catechin-epicatechin polymer having four to nine monomer units.

16. (Previously Presented) The composition according to Claim 1, wherein the polymers having four to nine monomer units consist essentially of catechin-epicatechin polymers of the formula:





wherein n has a value of from 2 to 7, and

R is

..... OH and  OH and the ratio of OH to  OH is 2 to 1,

R' is

..... OH and  OH and the ratio of OH to  OH is 1 to 2

giving a ratio of catechin to epicatechin in the upper terminal and middle of 2 to 1 and a 1 to 2 ratio of catechin to epicatechin in the lower terminal.

17. (Original) The composition of claim 16 wherein n has a value of 3.
18. (Original) The composition of claim 16 wherein n has a value of 5.
19. (Original) The composition of claim 16 wherein n has a value of 7.

21. (Currently Amended) A method of improving the memory of animals comprising administering to said animals an effective amount of a composition having an active ingredient ~~comprising~~ **consisting essentially of:**

an aqueous extract of buckwheat seed,
a fractionation product of an aqueous extract of buckwheat seed, and
a combination of said aqueous extract of buckwheat seed and said fractionation
d aqueous extract of buckwheat seed,



said polymers having a molecular weight of from about 1,000 to about 10,000, and

7

R is

..... OH and  OH and the ratio of OH to  OH is 2 to 1,

R' is

..... OH and  OH and the ratio of OH to  OH is 1 to 2

giving a ratio of catechin to epicatechin in the upper terminal and middle of 2 to 1 and a 1 to 2 ratio of catechin to epicatechin in the lower terminal

wherein the composition enhances an activity of protein kinase C (PKC), improves short time memory and alleviates decrease in space cognition caused by aging.

22. (New) A pharmaceutical product which includes as an agent, a polyphenol oligomer which is hot-water extracted from buckwheat seeds and contains catechin and epicatechins at a specific ratio,

wherein the polyphenol oligomer has 4 to 9 monomer units and said polyphenol oligomer has a molecular weight of about 1000 to about 10,000, and

which enhances an activity of protein kinase C (PKC), improves short time memory and alleviates decrease in space cognition caused by aging.